Why the study?
Does fondaparinux improve clinical safety and efficacy outcomes compared to unfractionated heparin in patients undergoing contemporary PCI?
Does fondaparinux improve clinical safety and efficacy outcomes compared to unfractionated heparin in patients undergoing contemporary PCI?
In a pilot study, fondaparinux demonstrated comparable safety and efficacy to unfractionated heparin in patients undergoing PCI, supporting its further evaluation in arterial thrombosis.
Fondaparinux offers comparable safety and efficacy to UFH in PCI; supports larger trials for arterial thrombosis.
In this pilot study of patients undergoing contemporary PCI, factor Xa inhibition with the synthetic anticoagulant fondaparinux in doses of 2.5 and 5.0 mg was comparable to UFH for clinical safety and efficacy outcomes. These data form the basis for further evaluation of fondaparinux in arterial thrombosis.
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: